|Bid||2.2800 x 2900|
|Ask||2.3000 x 1300|
|Day's Range||2.2200 - 2.3600|
|52 Week Range||2.1100 - 16.8000|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for FRLNLearn more
Key Insights Significant control over Freeline Therapeutics Holdings by private equity firms implies that the general...
Freeline Therapeutics Holdings plc (NASDAQ:FRLN) Q4 2022 Earnings Call Transcript April 4, 2023 Operator: Good day, everyone. Welcome to the Freeline Therapeutics Business Update Conference Call. At this time, all participants are in listen-only mode. After the company’s prepared remarks, there will be a question-and-answer session. Please be advised that today’s conference call is being […]
Freeline Therapeutics Holdings plc (NASDAQ: FRLN) further assessed its strategic priorities and decided to pause the development of FLT190 in Fabry disease to focus its resources on advancing FLT201, which has the potential to be a first- and best-in-class gene therapy for Gaucher disease type 1. Based on its preclinical data, Freeline believes FLT201 can potentially improve clinical outcomes for patients with Gaucher disease type 1 with a one-time therapy. The company is actively screening pati
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Freeline Therapeutics Holdings plc (NASDAQ: FRLN) has decided to focus its resources on FLT201 in Gaucher disease and FLT190 in Fabry disease. The company will stop investment in further development of FLT180a without a partner. Additionally, Freeline announced updated data from the two patients treated in the first cohort from the MARVEL-1 Phase 1/2 trial of FLT190 at a dose of 7.5e11 vg/kg. People with classic Fabry disease have little to no functional α-Gal A enzyme. Data exhibited elevated α
After losing some value lately, a hammer chart pattern has been formed for Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Earlier this month, Freeline Therapeutics Holdings PLC (NASDAQ: FRLN) reported 2Q22 earnings focusing on the pipeline's progress. Notably, the company said it is evaluating strategic options for FLT180a for hemophilia B and is reviewing how to streamline operations, including but not limited to seeking a partner to enable the continuation of FLT180a through Phase 3 development. Till the details on this potential pact are available, HC Wainwright is removing FLT180a from the model resulting in a
Absci, Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics are part of Zacks top Analyst Blog.
Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.
Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Small biotech Freeline Therapeutics Holdings plc (NASDAQ: FRLN) hopes new long-term data will help boost its case. The company announced that the New England Journal of Medicine (NEJM) published positive data, expanding upon previously announced long-term follow-up data for up to 3.5 years from the Phase 1/2 B-AMAZE trial of hemophilia B gene therapy candidate, FLT180a. Hemophilia is an inherited bleeding disorder caused by a deficiency in coagulation factor IX (FIX). Related: Freeline Posts Cas
Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Freeline Therapeutics Holdings plc (NASDAQ: FRLN) announced the presentation of safety and initial efficacy data from the first cohort of the Phase 1/2 B-LIEVE trial for FLT180a for hemophilia B. As of the data cut-off of May 23, 2022, a one-time FLT180a dose of 7.7e11 vg/kg generated a rapid increase of coagulation factor IX (FIX), reaching levels in the normal range (93, 92, and 80 IU/dL) for the three patients in cohort 1 through days 77, 56 and 36, respectively. FIX is an essential protein i